4//SEC Filing
Forman Stephen J. 4
Accession 0001641172-25-018284
CIK 0001335105other
Filed
Jul 7, 8:00 PM ET
Accepted
Jul 8, 9:33 PM ET
Size
24.1 KB
Accession
0001641172-25-018284
Insider Transaction Report
Form 4
Forman Stephen J.
Director
Transactions
- Award
Options to Purchase Common Stock
2025-06-30+7,754→ 7,754 totalExercise: $0.91From: 2025-06-30Exp: 2030-06-30→ Common (7,754 underlying) - Award
Options to Purchase Common Stock
2025-06-30+10,000→ 10,000 totalExercise: $0.91From: 2025-09-30Exp: 2030-06-30→ Common (10,000 underlying)
Holdings
- 5,851
Options to Purchase Common Stock
Exercise: $1.21From: 2025-03-31Exp: 2030-03-31→ Common (5,851 underlying) - 3,858
Options to Purchase Common Stock
Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (3,858 underlying) - 833
Options to Purchase Common Stock
Exercise: $9.00From: 2017-10-16Exp: 2022-10-16→ Common (833 underlying) - 833
Options to Purchase Common Stock
Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying) - 3,018
Options to Purchase Common Stock
Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (3,018 underlying) - 2,105(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $57.00From: 2018-12-07Exp: 2022-12-07→ Common (2,105 underlying) - 1,667(indirect: By Trust)
Warrants to Purchase Common Stock
Exercise: $60.00From: 2018-12-07Exp: 2022-12-07→ Common (1,667 underlying) - 3,030
Options to Purchase Common Stock
Exercise: $2.33From: 2025-01-20Exp: 2030-01-20→ Common (3,030 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying) - 10,000
Options to Purchase Common Stock
Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying) - 5,000
Options to Purchase Common Stock
Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying)
Footnotes (2)
- [F1]Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
- [F2]Effective June 30, 2025 the reporting person was granted stock options in aggregate of 7,754 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Documents
Issuer
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
CIK 0001335105
Entity typeother
Related Parties
1- filerCIK 0001676461
Filing Metadata
- Form type
- 4
- Filed
- Jul 7, 8:00 PM ET
- Accepted
- Jul 8, 9:33 PM ET
- Size
- 24.1 KB